

Athimalaipet V Ramanan

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/1755330/athimalaipet-v-ramanan-publications-by-year.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

111
papers

3,647
citations

31
h-index

59
g-index

139
ext. papers

5,006
ext. citations

5.8
avg, IF

5.73
L-index

#	Paper	IF	Citations
111	Efficacy and safety of baricitinib plus standard of care for the treatment of critically ill hospitalised adults with COVID-19 on invasive mechanical ventilation or extracorporeal membrane oxygenation: an exploratory, randomised, placebo-controlled trial.. <i>Lancet Respiratory Medicine, the, 2022,</i>	35.1	15
110	The neglected and untreated pains of CRMO and SAPHO syndrome.. <i>Rheumatology, 2022,</i>	3.9	2
109	Comment on: The neglected and untreated pains of CRMO and SAPHO syndrome: Reply.. <i>Rheumatology, 2022,</i>	3.9	
108	Rituximab therapy in ROHHAD(NET) syndrome.. <i>Journal of Pediatric Endocrinology and Metabolism, 2022,</i>	1.6	1
107	Real world treatment of juvenile-onset systemic lupus erythematosus: Data from the UK JSLE cohort study.. <i>Clinical Immunology, 2022, 109028</i>	9	0
106	Chronic Recurrent Multifocal Osteomyelitis (Chronic Non-infective Osteitis) 2022, 371-382		
105	Tofacitinib in juvenile idiopathic arthritis. <i>Lancet, The, 2021, 398, 1943-1945</i>	40	2
104	Clinical effectiveness and safety of baricitinib for the treatment of juvenile idiopathic arthritis-associated uveitis or chronic anterior antinuclear antibody-positive uveitis: study protocol for an open-label, adalimumab active-controlled phase 3 clinical trial (JUVE-BRIGHT). <i>Trials, 2021, 22, 689</i>	2.8	6
103	Neuropsychiatric involvement in juvenile-onset systemic lupus erythematosus: Data from the UK Juvenile-onset systemic lupus erythematosus cohort study. <i>Lupus, 2021, 30, 1955-1965</i>	2.6	3
102	Anakinra in Refractory Multisystem Inflammatory Syndrome in Children (MIS-C). <i>Indian Pediatrics, 2021, 58, 994-996</i>	1.2	2
101	Limited sensitivity and specificity of the ACR/EULAR-2019 classification criteria for SLE in JSLE?-observations from the UK JSLE Cohort Study. <i>Rheumatology, 2021, 60, 5271-5281</i>	3.9	8
100	COVID-19 vasculitis and novel vasculitis mimics. <i>Lancet Rheumatology, The, 2021, 3, e224-e233</i>	14.2	64
99	Targeting hyperinflammation in infection: can we harness the COVID-19 therapeutics momentum to end the dengue drugs drought?. <i>Lancet Microbe, The, 2021, 2, e277-e278</i>	22.2	0
98	"Environmental risk factors associated with juvenile idiopathic arthritis associated uveitis: a systematic review of the literature". <i>Journal of Ophthalmic Inflammation and Infection, 2021, 11, 15</i>	2.3	3
97	Tocilizumab plus standard care versus standard care in patients in India with moderate to severe COVID-19-associated cytokine release syndrome (COVINTOC): an open-label, multicentre, randomised, controlled, phase 3 trial. <i>Lancet Respiratory Medicine, the, 2021, 9, 511-521</i>	35.1	96
96	COVID-19: angiotensin II in development of lung immunothrombosis and vasculitis mimics - Author's reply. <i>Lancet Rheumatology, The, 2021, 3, e326</i>	14.2	0
95	Improving clinical paediatric research and learning from COVID-19: recommendations by the Conect4Children expert advice group. <i>Pediatric Research, 2021,</i>	3.2	2

94	Juvenile Idiopathic Arthritis Associated Uveitis. <i>Children</i> , 2021 , 8,	2.8	1
93	Platelet Glycoprotein Ib EChain as a Putative Therapeutic Target for Juvenile Idiopathic Arthritis: A Mendelian Randomization Study. <i>Arthritis and Rheumatology</i> , 2021 , 73, 693-701	9.5	3
92	Changing evidence over time: updated meta-analysis regarding anti-TNF efficacy in childhood chronic uveitis. <i>Rheumatology</i> , 2021 , 60, 568-587	3.9	8
91	The management of Sjögren's syndrome: British Society for Rheumatology guideline scope. <i>Rheumatology</i> , 2021 , 60, 2122-2127	3.9	0
90	A national consensus management pathway for paediatric inflammatory multisystem syndrome temporally associated with COVID-19 (PIMS-TS): results of a national Delphi process. <i>The Lancet Child and Adolescent Health</i> , 2021 , 5, 133-141	14.5	121
89	Clinical and laboratory phenotypes in juvenile-onset Systemic Lupus Erythematosus across ethnicities in the UK. <i>Lupus</i> , 2021 , 30, 597-607	2.6	8
88	Subcutaneous dosing regimens of tocilizumab in children with systemic or polyarticular juvenile idiopathic arthritis. <i>Rheumatology</i> , 2021 , 60, 4568-4580	3.9	5
87	Immune cartography of macrophage activation syndrome in the COVID-19 era. <i>Nature Reviews Rheumatology</i> , 2021 , 17, 145-157	8.1	30
86	It is good to have a target in mind's qualitative views of patients and parents informing a treat to target clinical trial in juvenile-onset systemic lupus erythematosus. <i>Rheumatology</i> , 2021 , 60, 5630-5641	3.9	5
85	Rise in children presenting with periodic fever, aphthous stomatitis, pharyngitis and adenitis syndrome during the COVID-19 pandemic. <i>Archives of Disease in Childhood</i> , 2021 , 106, e49	2.2	2
84	Establishing core domain sets for Chronic Nonbacterial Osteomyelitis (CNO) and Synovitis, Acne, Pustulosis, Hyperostosis, Osteitis (SAPHO): A report from the OMERACT 2020 special interest group. <i>Seminars in Arthritis and Rheumatism</i> , 2021 , 51, 957-961	5.3	0
83	Systemic Immunomodulatory Therapy in Pediatric Uveitis. <i>Advances in Ophthalmology and Optometry</i> , 2021 , 6, 87-100	0.5	
82	Steroids or intravenous immunoglobulin as first line in MIS-C in LMICs. <i>Lancet Rheumatology</i> , 2021 , 3, e615-e616	14.2	2
81	Efficacy and safety of baricitinib for the treatment of hospitalised adults with COVID-19 (COV-BARRIER): a randomised, double-blind, parallel-group, placebo-controlled phase 3 trial. <i>Lancet Respiratory Medicine</i> , 2021 , 9, 1407-1418	35.1	123
80	Anakinra in Refractory Multisystem Inflammatory Syndrome in Children (MIS-C). <i>Indian Pediatrics</i> , 2021 , 58, 994-996	1.2	1
79	Attainment of Low Disease Activity and Remission Targets reduces the risk of severe flare and new damage in Childhood Lupus. <i>Rheumatology</i> , 2021 ,	3.9	1
78	Hyperinflammatory Syndrome in Children Associated With COVID-19: Need for Awareness. <i>Indian Pediatrics</i> , 2020 , 57, 929-935	1.2	27
77	Coronavirus Disease 2019 (COVID-19) in Children - What We Know So Far and What We Do Not. <i>Indian Pediatrics</i> , 2020 , 57, 435-442	1.2	99

76	Artificial intelligence for interpretation of segments of whole body MRI in CNO: pilot study comparing radiologists versus machine learning algorithm. <i>Pediatric Rheumatology</i> , 2020 , 18, 47	3.5	5
75	Tocilizumab in patients with anti-TNF refractory juvenile idiopathic arthritis-associated uveitis (APTITUDE): a multicentre, single-arm, phase 2 trial. <i>Lancet Rheumatology, The</i> , 2020 , 2, e135-e141	14.2	35
74	Real-world or clinical trial data for treatment of children with rheumatic diseases?. <i>Rheumatology</i> , 2020 , 59, 707-708	3.9	1
73	Different corticosteroid induction regimens in children and young people with juvenile idiopathic arthritis: the SIRJIA mixed-methods feasibility study. <i>Health Technology Assessment</i> , 2020 , 24, 1-152	4.4	0
72	Aiming high: quantifying inflammation in systemic onset juvenile idiopathic arthritis (sJIA), a multi-faceted and complex inflammatory disease. <i>Rheumatology</i> , 2020 , 59, 3124-3126	3.9	1
71	Severe refractory Kawasaki disease in seven infants in the COVID-19 era. <i>Lancet Rheumatology, The</i> , 2020 , 2, e520	14.2	4
70	Whole-body MRI in the diagnosis of paediatric CNO/CRMO. <i>Rheumatology</i> , 2020 , 59, 2671-2680	3.9	13
69	Update on noninfectious uveitis in children and its treatment. <i>Current Opinion in Rheumatology</i> , 2020 , 32, 395-402	5.3	14
68	Discontinuing adalimumab in patients with controlled juvenile idiopathic arthritis-associated uveitis (ADJUST-Adalimumab in Juvenile Idiopathic Arthritis-associated Uveitis Stopping Trial): study protocol for a randomised controlled trial. <i>Trials</i> , 2020 , 21, 887	2.8	6
67	Areas of agreement in the management of childhood non-infectious chronic anterior uveitis in the UK. <i>British Journal of Ophthalmology</i> , 2020 , 104, 11-16	5.5	8
66	The risk of uveitis in patients with JIA receiving etanercept: the challenges of analysing real-world data. <i>Rheumatology</i> , 2020 , 59, 1391-1397	3.9	6
65	Same but different? A thematic analysis on adalimumab biosimilar switching among patients with juvenile idiopathic arthritis. <i>Pediatric Rheumatology</i> , 2019 , 17, 67	3.5	5
64	Adalimumab in Juvenile Idiopathic Arthritis-Associated Uveitis: 5-Year Follow-up of the Bristol Participants of the SYCAMORE Trial. <i>American Journal of Ophthalmology</i> , 2019 , 207, 170-174	4.9	23
63	Defining consensus opinion to develop randomised controlled trials in rare diseases using Bayesian design: An example of a proposed trial of adalimumab versus pamidronate for children with CNO/CRMO. <i>PLoS ONE</i> , 2019 , 14, e0215739	3.7	10
62	Recommendations for the management of hemophagocytic lymphohistiocytosis in adults. <i>Blood</i> , 2019 , 133, 2465-2477	2.2	318
61	Kawasaki disease: a prospective population survey in the UK and Ireland from 2013 to 2015. <i>Archives of Disease in Childhood</i> , 2019 , 104, 640-646	2.2	41
60	Toward Accelerated Authorization and Access to New Medicines for Juvenile Idiopathic Arthritis. <i>Arthritis and Rheumatology</i> , 2019 , 71, 1976-1984	9.5	5
59	Adalimumab in combination with methotrexate for refractory uveitis associated with juvenile idiopathic arthritis: a RCT. <i>Health Technology Assessment</i> , 2019 , 23, 1-140	4.4	10

58	Reply. <i>Ophthalmology</i> , 2019 , 126, e24-e25	7.3	
57	Magnetic resonance imaging of sacroiliitis in children: reply to Jalalvandi and Naderi. <i>Pediatric Radiology</i> , 2019 , 49, 281	2.8	
56	Cost-Effectiveness Analysis of Adalimumab for the Treatment of Uveitis Associated with Juvenile Idiopathic Arthritis. <i>Ophthalmology</i> , 2019 , 126, 415-424	7.3	14
55	Big data and stratified medicine: what does it mean for children?. <i>Archives of Disease in Childhood</i> , 2019 , 104, 389-394	2.2	7
54	Macrophage activation syndrome in adults: recent advances in pathophysiology, diagnosis and treatment. <i>Rheumatology</i> , 2019 , 58, 5-17	3.9	93
53	S100A12 and S100A8/9 proteins are biomarkers of articular disease activity in Blau syndrome. <i>Rheumatology</i> , 2018 , 57, 1299-1304	3.9	10
52	Paediatric rheumatology in 2017: Child-centred research is the key to progress. <i>Nature Reviews Rheumatology</i> , 2018 , 14, 69-70	8.1	1
51	Guidance on Noncorticosteroid Systemic Immunomodulatory Therapy in Noninfectious Uveitis: Fundamentals Of Care for Uveitis (FOCUS) Initiative. <i>Ophthalmology</i> , 2018 , 125, 757-773	7.3	97
50	Consensus-based recommendations for the management of uveitis associated with juvenile idiopathic arthritis: the SHARE initiative. <i>Annals of the Rheumatic Diseases</i> , 2018 , 77, 1107-1117	2.4	70
49	Chronic recurrent multifocal osteomyelitis in children and adults: current understanding and areas for development. <i>Rheumatology</i> , 2018 , 57, 41-48	3.9	24
48	Blau Syndrome-Associated Uveitis: Preliminary Results From an International Prospective Interventional Case Series. <i>American Journal of Ophthalmology</i> , 2018 , 187, 158-166	4.9	40
47	A phase II trial protocol of Tocilizumab in anti-TNF refractory patients with JIA-associated uveitis (the APTITUDE trial). <i>BMC Rheumatology</i> , 2018 , 2, 4	2.9	18
46	Outcomes of non-infectious Paediatric uveitis in the era of biologic therapy. <i>Pediatric Rheumatology</i> , 2018 , 16, 51	3.5	39
45	Proposed Core Set of Items for Measuring Disease Activity in Systemic Juvenile Idiopathic Arthritis. <i>Journal of Rheumatology</i> , 2018 , 45, 115-121	4.1	6
44	Protective parents and permissive children: what qualitative interviews with parents and children can tell us about the feasibility of juvenile idiopathic arthritis trials. <i>Pediatric Rheumatology</i> , 2018 , 16, 76	3.5	3
43	Multi-centre national audit of juvenile localised scleroderma: describing current UK practice in disease assessment and management. <i>Pediatric Rheumatology</i> , 2018 , 16, 80	3.5	13
42	Chronic non bacterial osteitis- a multicentre study. <i>Pediatric Rheumatology</i> , 2018 , 16, 74	3.5	18
41	The burden of systemic juvenile idiopathic arthritis for patients and caregivers: an international survey and retrospective chart review. <i>Clinical and Experimental Rheumatology</i> , 2018 , 36, 920-928	2.2	8

40	Think about the CS (in custard and crackers). <i>Archives of Disease in Childhood: Education and Practice Edition</i> , 2018 , 103, 304-306	0.5	3
39	Diagnosing haemophagocytic syndrome. <i>Archives of Disease in Childhood</i> , 2017 , 102, 279-284	2.2	32
38	Adalimumab plus Methotrexate for Uveitis in Juvenile Idiopathic Arthritis. <i>New England Journal of Medicine</i> , 2017 , 376, 1637-1646	59.2	218
37	Cross sectional, qualitative thematic analysis of patient perspectives of disease impact in juvenile idiopathic arthritis-associated uveitis. <i>Pediatric Rheumatology</i> , 2017 , 15, 58	3.5	15
36	Juvenile idiopathic arthritis-associated uveitis. <i>Best Practice and Research in Clinical Rheumatology</i> , 2017 , 31, 517-534	5.3	31
35	Cardiac involvement as a presenting feature of eosinophilic granulomatosis with polyangiitis in childhood. <i>Clinical and Experimental Rheumatology</i> , 2017 , 35 Suppl 103, 225	2.2	
34	Interstitial Lung Disease Caused by STING-associated Vasculopathy with Onset in Infancy. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2016 , 194, 639-42	10.2	41
33	Expert consensus on dynamics of laboratory tests for diagnosis of macrophage activation syndrome complicating systemic juvenile idiopathic arthritis. <i>RMD Open</i> , 2016 , 2, e000161	5.9	46
32	2016 Classification Criteria for Macrophage Activation Syndrome Complicating Systemic Juvenile Idiopathic Arthritis: A European League Against Rheumatism/American College of Rheumatology/Paediatric Rheumatology International Trials Organisation Collaborative Initiative. <i>Annals of the Rheumatic Diseases</i> , 2016 , 75, 481-9	2.4	247
31	Managing juvenile idiopathic arthritis-associated uveitis. <i>Survey of Ophthalmology</i> , 2016 , 61, 197-210	6.1	27
30	Macrophage Activation Syndrome. <i>Indian Journal of Pediatrics</i> , 2016 , 83, 248-53	3	25
29	Juvenile idiopathic arthritis-associated uveitis. <i>Pediatric Rheumatology</i> , 2016 , 14, 27	3.5	71
28	2016 Classification Criteria for Macrophage Activation Syndrome Complicating Systemic Juvenile Idiopathic Arthritis: A European League Against Rheumatism/American College of Rheumatology/Paediatric Rheumatology International Trials Organisation Collaborative Initiative. <i>Arthritis and Rheumatology</i> , 2016 , 68, 566-76	9.5	216
27	Uveitis associated with juvenile idiopathic arthritis. <i>Nature Reviews Rheumatology</i> , 2015 , 11, 338-48	8.1	57
26	A60: Optic Nerve and Retinal Features in Uveitis Associated With Juvenile Systemic Granulomatous Disease (Blau Syndrome). <i>Arthritis and Rheumatology</i> , 2014 , 66, S89-S89	9.5	1
25	Fifteen-minute consultation: a structured approach to the management of a child or adolescent with back pain. <i>Archives of Disease in Childhood: Education and Practice Edition</i> , 2014 , 99, 202-7	0.5	2
24	Efficacy of pamidronate therapy in children with chronic non-bacterial osteitis: disease activity assessment by whole body magnetic resonance imaging. <i>Rheumatology</i> , 2014 , 53, 1973-6	3.9	47
23	The child with joint pain in primary care. <i>Best Practice and Research in Clinical Rheumatology</i> , 2014 , 28, 888-906	5.3	9

22	A118: Laboratory Investigation of the Role of Toll-Like Receptors on Kidney Cells in Pathogenesis of Lupus Nephritis. <i>Arthritis and Rheumatology</i> , 2014 , 66, S155-S155	9.5	1
21	A75: Proposal of the Bristol Criteria for the Diagnosis of Chronic Non-bacterial Osteitis From a Cohort of 41 Patients. <i>Arthritis and Rheumatology</i> , 2014 , 66, S107-S107	9.5	6
20	Development of new classification criteria for macrophage activation syndrome complicating systemic juvenile idiopathic arthritis. <i>Pediatric Rheumatology</i> , 2014 , 12,	3.5	6
19	A randomised controlled trial of the clinical effectiveness, safety and cost-effectiveness of adalimumab in combination with methotrexate for the treatment of juvenile idiopathic arthritis associated uveitis (SYCAMORE Trial). <i>Trials</i> , 2014 , 15, 14	2.8	64
18	Renal hypertension: an unusual cause for a common problem. <i>European Journal of Pediatrics</i> , 2013 , 172, 711-2	4.1	1
17	Chronic recurrent multifocal osteomyelitis. <i>Advances in Experimental Medicine and Biology</i> , 2013 , 764, 99-107	3.6	18
16	Unusual presentation of spinal involvement in a child with chronic recurrent multifocal osteomyelitis. <i>International Journal of Rheumatic Diseases</i> , 2013 , 16, 477-9	2.3	1
15	Idiopathic chondrolysis in a child: think beyond JIA. <i>International Journal of Rheumatic Diseases</i> , 2012 , 15, e58-9	2.3	3
14	Juvenile dermatomyositis: A review of clinical features and management. <i>Indian Journal of Rheumatology</i> , 2012 , 7, 80-86	0.5	4
13	Proposed outcome measures for prospective clinical trials in juvenile idiopathic arthritis-associated uveitis: a consensus effort from the multinational interdisciplinary working group for uveitis in childhood. <i>Arthritis Care and Research</i> , 2012 , 64, 1365-72	4.7	73
12	Juvenile systemic lupus erythematosus: review of clinical features and management. <i>Indian Pediatrics</i> , 2011 , 48, 879-87	1.2	20
11	The era of biologics for children and young people with rheumatological diseaseP97. Therapeutic Advances in Juvenile Idiopathic Arthritis. <i>Rheumatology</i> , 2011 , 50, iii25-iii26	3.9	
10	Non-infectious pediatric uveitis: an update on immunomodulatory management. <i>Paediatric Drugs</i> , 2009 , 11, 229-41	4.2	22
9	A case of macrophage activation syndrome successfully treated with anakinra. <i>Nature Clinical Practice Rheumatology</i> , 2008 , 4, 615-20		104
8	The diagnostic significance of soluble CD163 and soluble interleukin-2 receptor alpha-chain in macrophage activation syndrome and untreated new-onset systemic juvenile idiopathic arthritis. <i>Arthritis and Rheumatism</i> , 2007 , 56, 965-71		257
7	Use of infliximab in juvenile onset rheumatological disease-associated refractory uveitis: efficacy in joint and ocular disease. <i>Annals of the Rheumatic Diseases</i> , 2007 , 66, 840-1	2.4	44
6	Treatment approaches to juvenile dermatomyositis. <i>Expert Opinion on Pharmacotherapy</i> , 2004 , 5, 1509-15		5
5	Favorable outcome in patients with renal involvement complicating macrophage activation syndrome in systemic onset juvenile rheumatoid arthritis. <i>Journal of Rheumatology</i> , 2004 , 31, 2068-70	4.1	16

4	Use of methotrexate in juvenile idiopathic arthritis. <i>Archives of Disease in Childhood</i> , 2003 , 88, 197-200	2.2	88
3	Macrophage activation syndrome following initiation of etanercept in a child with systemic onset juvenile rheumatoid arthritis. <i>Journal of Rheumatology</i> , 2003 , 30, 401-3	4.1	94
2	Baricitinib plus Standard of Care for Hospitalised Adults with COVID-19 on Invasive Mechanical Ventilation or Extracorporeal Membrane Oxygenation: Results of a Randomised, Placebo-Controlled Trial		7
1	Efficacy and safety of baricitinib in patients with COVID-19 infection: Results from the randomised, double-blind, placebo-controlled, parallel-group COV-BARRIER phase 3 trial		12